Skip to main content
. Author manuscript; available in PMC: 2020 May 22.
Published in final edited form as: ACS Appl Mater Interfaces. 2019 May 13;11(20):18074–18089. doi: 10.1021/acsami.9b01343

Figure 8.

Figure 8.

Representative immune-labeled cross sections of tumors treated with phosphate buffer saline (A-C) and prodrug nanoparticles (D-F). Sections were incubated with pSTAT-3 antibody (red) and background protein β-actin (green) around cell nuclei stained with DAPI (blue) to show significantly high level of pSTAT-3 in phosphate buffer saline treated tumors compared to treated with Pro-nifuroxazide nanoparticles.